Results 201 to 210 of about 1,913,070 (304)

Transcriptomic and miRNA-Target Pathway Analysis of the DLK1-DIO3 Imprinted microRNA Cluster in Chronic Lymphocytic Leukemia. [PDF]

Diseases
Markopoulos GS, Simos YV, Tsamis KI, Lakkas L, Hatzimichael E, Kapsali E, Peschos D, Benetatos L.   +7 more
europepmc   +1 more source

Extragenital <i>Mycoplasma hominis</i> infection following obinutuzumab therapy in a patient with chronic lymphocytic leukemia. [PDF]

IDCases
Benandi K, Blanton LS.
europepmc   +1 more source

EHA Guidelines on management of chronic lymphocytic leukemia and Richter transformation. [PDF]

Hemasphere
Eichhorst B, Ghia P, Bosch F, Clifford R, Gregor M, Guieze R, Kater AP, Niemann CU, Pospisilova S, Robak T, Schuh A, Stamatopoulos K, Tadmor T, York N.   +13 more
europepmc   +1 more source

ZMYM3 mutations modulate histone acetylation and cooperate with NOTCH1 mutations in chronic lymphocytic leukemia. [PDF]

Blood Adv
Rodríguez-Sánchez A, Pérez-Carretero C, Corchete-Sánchez LA, Miguel-García C, Santos-Mínguez S, Villaverde-Ramiro Á, Dávila J, García de Coca A, Galende J, Juanes-Velasco P, Fuentes M, Benito-Sánchez R, Rodríguez-Vicente AE, Quijada-Álamo M, Hernández Rivas JM.   +14 more
europepmc   +1 more source

Chronic Lymphocytic Leukemia: Molecular Pathologies and Therapeutic Strategies. [PDF]

Int J Mol Sci
Meza K, Barrientos Risso C, Shah A, Romagnoli C, Sandoval J, Brauchle Y, Lyubimova A, Santos L, Goya Balaguer E, Barrientos J.   +9 more
europepmc   +1 more source

Lenalidomide maintenance after initial immunochemotherapy in chronic lymphocytic leukaemia—Final analysis of the international phase III CLL6 RESIDUUM study of the ALLG and FILO groups

British Journal of Haematology, EarlyView.
Summary Most patients treated for chronic lymphocytic leukaemia (CLL) fail to achieve measurable residual disease (MRD) negativity. The role of maintenance with the immunomodulatory drug lenalidomide in these patients is unclear. A randomised multicentre phase III trial (ACTRN12610000060044) was conducted in Australia and France to assess the effect of
Thérèse Aurran‐Schleinitz, Rémi Letestu, Mary Sartor, Stephen Mulligan, Marie C. Béné, Gavin Cull, Dennis Carney, William Renwick, Andrew Grigg, Cecily Forsyth, Gregory Hapgood, Emma Verner, Rosemary Harrup, Pauline Warburton, Kylie Mason, Richard Eek, Wojciech Janowski, Jean Pierre Vilque, Maya Latimer, Laurent Voillat, Sophie De Guibert, Bernard Drenou, Robert Blum, Caroline Dartigeas, Lachlan Hayes, Nicolas Daguindau, Mourad Tiab, Véronique Leblond, Andrew Shearer, Masa Lasica, Pierre Morel, Bohrane Slama, Anne Banos, Annie Brion, Emmanuelle Ferrant, Jessica Michel, Cécile Tomowiak, Edward Morris, Hanlon Sia, Kelly Kratzing, Belinda E. Butcher, Abdelmalek Dahmani, Stephen Robert Larsen, Piers Blombery, Florence Cymbalista, David J. Gottlieb   +45 more
wiley   +1 more source

Resistance pathways and next-generation treatments in chronic lymphocytic leukemia. [PDF]

Discov Oncol
Bellemrrabet R, Rachid E, Lahmouad M, Aboussaleh Y, Al Abdulmonem W, Bouyahya A, Abboussi O, Amahdar L.   +7 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, EarlyView.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Atypical chronic lymphocytic leukemia with biallelic 13Q deletion. [PDF]

Hematol Transfus Cell Ther
Roldán Galiacho V, Altuna Tellechea L, Alonso Varela M, Diez de Lezcano Manrique deLara I.   +3 more
europepmc   +1 more source

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source